Subscribe

Recent Articles

Popular Posts

Site search

Follow Us

Tag: Business and Professions Code

Fallout Over Genetic Testing Controversy Continues

Written by on Wednesday, June 18th, 2008

The fallout over California’s attempts to regulate genetic testing continued today as more facts over the California action came to light.

As the California Biotech Law Blog reported earlier this week , California’s Department of Health sent out cease and desist letters to thirteen genetic testing companies, including Navigenics, Inc. and 23andMe, Inc, demanding that these companies halt sales in the state until they can demonstrate that their laboratories are certified by the state and federal governments and that the tests have been ordered by a doctor as required by state law.

Wired.com is following the controversy, and has obtained copies of the letters that went out to at least two of the recipients.  Alleging that the companies violated California law, the letters cite eight statutory provisions of California’s Business and Professions Code in support of their allegations: Sections 1206(a)(4), 1220(d), 1241, 1246.5, 1265(a)(1), 1281, 1287(b)(3), 1288. 

These provisions state as follows:

    • 1206(a)(4):"Clinical laboratory test or examination" means the detection,
      identification, measurement, evaluation, correlation, monitoring,
      and reporting of any particular analyte, entity, or substance within
      a biological specimen for the purpose of obtaining scientific data
      which may be used as an aid to ascertain the presence, progress, and
      source of a disease or physiological condition in a human being, or
      used as an aid in the prevention, prognosis, monitoring, or treatment
      of a physiological or pathological condition in a human being, or
      for the performance of nondiagnostic tests for assessing the health
      of an individual.

 

    • 1220(d) (1) Each clinical laboratory shall perform all clinical
      laboratory tests or examinations classified as waived under CLIA in
      conformity with the manufacturer’s instructions.
         (2) Except for those clinical laboratories performing only tests
      or examinations classified as waived under CLIA, each clinical
      laboratory shall establish and maintain all of the following:
         (A) A patient test management system that meets the standards of
      CLIA in Subpart J (commencing with Section 493.1101) of Title 42 of
      the Code of Federal Regulations.
         (B) A quality control program that meets the requirements of CLIA
      in Subpart K (commencing with Section 493.1201) of Title 42 of the
      Code of Federal Regulations.
         (C) A comprehensive quality assurance program that meets the
      standards of CLIA in Subpart P (commencing with Section 493.1701) of
      Title 42 of the Code of Federal Regulations.

 

    • 1241: This chapter applies to all clinical laboratories in
      California or receiving biological specimens originating in
      California for the purpose of performing a clinical laboratory test
      or examination, and to all persons performing clinical laboratory
      tests or examinations or engaging in clinical laboratory practice in
      California or on biological specimens originating in California,
      except as provided in subdivision (b).
         (b) This chapter shall not apply to any of the following clinical
      laboratories, or to persons performing clinical laboratory tests or
      examinations in any of the following clinical laboratories:
         (1) Those owned and operated by the United States of America, or
      any department, agency, or official thereof acting in his or her
      official capacity to the extent that the Secretary of the federal
      Department of Health and Human Services has modified the application
      of CLIA requirements to those laboratories.
         (2) Public health laboratories, as defined in Section 1206.
         (3) Those that perform clinical laboratory tests or examinations
      for forensic purposes only.
         (4) Those that perform clinical laboratory tests or examinations
      for research and teaching purposes only and do not report or use
      patient-specific results for the diagnosis, prevention, or treatment
      of any disease or impairment of, or for the assessment of the health
      of, an individual.
         (5) Those that perform clinical laboratory tests or examinations
      certified by the National Institutes on Drug Abuse only for those
      certified tests or examinations.  However, all other clinical
      laboratory tests or examinations conducted by the laboratory are
      subject to this chapter.
         (6) Those that register with the State Department of Health
      Services pursuant to subdivision (c) to perform blood glucose testing
      for the purposes of monitoring a minor child diagnosed with diabetes
        if the person performing the test has been entrusted with the care
      and control of the child by the child’s parent or legal guardian and
      provided that all of the following occur:
         (A) The blood glucose monitoring test is performed with a blood
      glucose monitoring instrument that has been approved by the federal
      Food and Drug Administration for sale over the counter to the public
      without a prescription.
         (B) The person has been provided written instructions by the child’
      s health care provider or an agent of the child’s health care
      provider in accordance with the manufacturer’s instructions on the
      proper use of the monitoring instrument and the handling of any
      lancets, test strips, cotton balls, or other items used during the
      process of conducting a blood glucose test.
         (C) The person, receiving written authorization from the minor’s
      parent or legal guardian, complies with written instructions from the
      child’s health care provider, or an agent of the child’s health care
      provider, regarding the performance of the test and the operation of
      the blood glucose monitoring instrument, including how to determine
      if the results are within the normal or therapeutic range for the
      child, and any restriction on activities or diet that may be
      necessary.
         (D) The person complies with specific written instructions from
      the child’s health care provider or an agent of the child’s health
      care provider regarding the identification of symptoms of
      hypoglycemia or hyperglycemia, and actions to be taken when results
      are not within the normal or therapeutic range for the child.  The
      instructions shall also contain the telephone number of the child’s
      health care provider and the telephone number of the child’s parent
      or legal guardian.
         (E) The person records the results of the blood glucose tests and
      provides them to the child’s parent or legal guardian on a daily
      basis.
         (F) The person complies with universal precautions when performing
      the testing and posts a list of the universal precautions in a
      prominent place within the proximity where the test is conducted.
         (7) Those individuals who perform clinical laboratory tests or
      examinations, approved by the federal Food and Drug Administration
      for  sale to the public without a prescription in the form of an
      over-the-counter test kit, on their own bodies or on their minor
      children or legal wards.
         (8) Those certified emergency medical technicians and licensed
      paramedics providing basic life support services or advanced life
      support services as defined in Section 1797.52 of the Health and
      Safety Code who perform only blood glucose tests that are classified
      as waived clinical laboratory tests under CLIA, if the provider of
      those services obtains a valid certificate of waiver and complies
      with all other requirements for the performance of waived clinical
      laboratory tests under applicable federal regulations.
         (c) Any place where blood glucose testing is performed pursuant to
      paragraph (6) of subdivision (b) shall register by notifying the
      State Department of Health Services in writing no later than 30 days
      after testing has commenced.  Registrants pursuant to this
      subdivision shall not be required to pay any registration or renewal
      fees nor shall they be subject to routine inspection by the State
      Department of Health Services.

 

    • 1246.5: Notwithstanding any other provision of law, any person may
      request, and any licensed clinical laboratory or public health
      laboratory may perform, the laboratory tests specified in this
      section.  A registered clinical laboratory may perform the laboratory
      tests specified in this section if the test is subject to a
      certificate of waiver under CLIA and the laboratory has registered
      with the department under paragraph (2) of subdivision (a) of Section
      1265. A program for nondiagnostic general health assessment that
      includes a laboratory test specified in this section shall comply
      with the provisions of Section 1244.  The results from any test may
      be provided directly to the person requesting the test if the test is
      on or for his or her own body.  These test results shall be provided
      in a manner that presents clear information and that identifies
      results indicating the need for referral to a physician and surgeon.

         The tests that may be conducted pursuant to this section are:
      pregnancy, glucose level, cholesterol, occult blood, and any other
      test for which there is a test for a particular analyte approved by
      the federal Food and Drug Administration for sale to the public
      without a prescription in the form of an over-the-counter test kit.
      A test approved only as an over-the-counter collection device may not
      be conducted pursuant to this section.

 

    • 1265(a)(1):A clinical laboratory performing clinical laboratory
      tests or examinations classified as of moderate or of high complexity
      under CLIA shall obtain a clinical laboratory license pursuant to
      this chapter.  The department shall issue a clinical laboratory
      license to any person who has applied for the license on forms
      provided by the department and who is found to be in compliance with
      this chapter and the regulations pertaining thereto.  No clinical
      laboratory license shall be issued by the department unless the
      clinical laboratory and its personnel meet the CLIA requirements for
      laboratories performing tests or examinations classified as of
      moderate or high complexity, or both.

 

    • 1281:It is unlawful for any person to own, operate, maintain,
      direct, or engage in the business of operating a clinical laboratory,
      as defined in this chapter, unless he or she possesses a valid
      clinical laboratory license issued by the department.  In the event a
      health facility does not perform clinical laboratory services, but
      provides laboratory services to its patients under an agreement with
      another person or entity that holds and is operating under a valid
      clinical laboratory license, the health facility shall not be
      required to obtain a clinical laboratory license.

 

 

    • 1287(b)(3):  The enforcement remedies provided under this section are not
      exclusive, and shall not preclude the use of any other criminal or
      civil remedy.  However, an act or omission punishable in different
      ways by this section and any other provision of law shall not be
      punished under more than one provision.  Under those circumstances,
      the penalty to be imposed shall be determined as set forth in Section
      654 of the Penal Code.

 

    • 1288:Any person conducting or operating a clinical laboratory may
      accept assignments for tests only from and make reports only to
      persons licensed under the provisions of law relating to the healing
      arts or their representatives.  This section does not prohibit the
      acceptance of evaluation specimens for proficiency testing or
      referral of specimens or such assignment from one clinical laboratory
      to another clinical laboratory, either licensed or exempt under this
      chapter, providing the report indicates clearly the laboratory
      performing the test.  A report of results issuing from a clinical
      laboratory shall show clearly the name and address of the laboratory
      and the name of the director.

 

The letters demand that the party submit a plan before June 23, 2008 advising how the company will prevent further violation of the law.

It is impossible to determine from these letters whether or not these companies actually are in violation of the law;  however, assuming the allegations are in fact accurate, is this really the whole story?  Or is something else actually responsible for this "attack" on genetic testing companies?  What is prompting this interest in genetic testing?

I cannot help but wonder if the medical community is at the heart of this controversy.  But if this is in fact the case, what is the issue?  Is there a concern by doctors that they are going to be found guilty of malpractice simply as a result of something they either overlook or do not know how to respond to in the genetic testing report?  As we suggested in our previous blog posting, there is certainly some debate as to how accurate various genetic tests actually are and what, if anything, should be done in response to certain results.  On the other hand, is there a fear by the medical community that the public will not know how to handle the data in the report?  Or is there at the heart of this issue an entirely different matter entirely?

It is interestng that in the same week that this controversy has erupted, Newsweek ran a story about Dean Ornish’s new book, where he looks at how changing lifestyle can change genes.  The prospect of potentially changing your genetic predisposition by making lifestyle changes is perhaps the best argument for why the public should have direct access to these tests.  Thomas Goetz of Wired.com also makes a compelling argument for direct access, arguing that "Frankly, it’s insulting and a curtailment of my rights to put a gatekeeper between me and my DNA." 

To date, this controversy has erupted in only two states: New York and California.  There are forty-eight other states yet to take this issue up.  Those states will be looking to New York and California to see how they deal with the controversy.  Perhaps the California legislature should jump to the forefront of this issue and look at changing the law to ensure direct public access to genetic testing.  Such an action would undoubtedly set an important precedent for the other forty-nine states, which might very well follow in California’s footsteps.  California: will you rise to the challenge? 

The California Biotech Law Blog will continue following this controversy as it further unfolds.

1,220 total views, 1 views today


Category: Biotech Industry News  |  1 Comment

© 2008-2015 The Prinz Law Office. All rights reserved.

The Prinz Law Office | Silicon Valley, CA | Los Angeles, CA | Orange County, CA | San Diego, CA | Atlanta, GA | Tel: 1.800.884.2124

Mailing Address: 117 Bernal Rd., Suite 70-110, San Jose, CA 95119; Silicon Valley Office: San Jose- 2033 Gateway Place, Suite 500, San Jose, CA 95110 (408)884-2854; Los Angeles Office: 3110 Main St., Building C, Santa Monica, CA 90405 (310)907-9218; Orange County Office: 100 Spectrum Center Drive, 9th Floor, Irvine, CA 92618 (949)236-6777; San Diego Office: 4455 Murphy Canyon Road, Suite 100, San Diego, CA 92123 (619)354-2727 Atlanta Office: 1000 Parkwood Circle, Suite 900, Atlanta, Georgia 30339 (404)479-2470

Biotech Transactions Lawyer & Attorney: Serving Silicon Valley, San Jose, San Francisco, San Diego, Los Angeles, Orange County, Irvine, Anaheim, Santa Monica, Silicon Beach, Atlanta. Licensed in California and Georgia.
Follow

Get every new post delivered to your Inbox

Join other followers